SAN DIEGO, April 2, 2025 -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, and preclinical results from the Company's SMARCA2 monovalent direct degrader and CDK2 molecular glue degrader programs will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, IL.
"We are thrilled that our research involving our selective degrader programs for SMARCA2, CDK2 and IKZF2 will be showcased prominently at AACR 2025, including during two oral presentations, and we look forward to sharing our clinical safety and PK/PD data with PLX-4545," said Jorge F. DiMartino, MD, PhD, Chief Medical Officer of Plexium. "AACR is one of the most important oncology meetings in the world, and we are excited to highlight our highly differentiated portfolio of next-generation monovalent targeted protein degraders."
Oral Presentation Details:
Title: "Discovery and characterization of novel, potent and selective CDK2 molecular glue degrader against CCNE1-amplified tumors"
Session: MS.ET09.01 - Degraders and Glues
Abstract Number: 6375
Date and Time: April 29, 2:55 PM – 3:10 PM
Presenting Author: Leenus Martin, PhD
Title: "PLX-4545, a selective IKZF2 degrader, reprograms suppressive Tregs leading to tumor growth inhibition and combination benefit with immune checkpoint therapy"
Session: MS.ET09.01 - Degraders and Glues
Abstract Number: 6380
Date and Time: April 29, 4:10 PM – 4:25 PM
Presenting Author: Peggy Thompson, PhD
Poster Presentation Details:
Title: "Mechanistic characterization of selective monovalent direct degraders of SMARCA2"
Session: PO.ET09.04 - Degraders and Glues 1
Abstract Number: 404
Section: 18
Date and Time: April 27, 2025, 2:00 PM - 5:00 PM
Presenting Author: Julia Toth, PhD
Title: "Preclinical characterization of PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader"
Session: PO.ET09.10 - Degraders and Glues 2
Abstract Number: 1653
Section: 18
Date and Time: April 28, 2025, 9:00 AM - 12:00 PM
Presenting Author: Gregory Parker, PhD
Title: "A first in humans trial of PLX-4545, a molecular glue degrader of IKZF2, in healthy volunteers, shows pharmacologic modulation of Tregs at well-tolerated doses"
Session Title: PO.CT01.02. First-in-Human Phase I Clinical Trials 2
Abstract Number: CT150
Section: 48
Date and Time: April 29, 2025, 9:00 AM – 12 PM
Presenting Author: Jorge DiMartino, MD, PhD
About Plexium Inc.
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent degraders that address the limitations of first-generation heterobifunctional degraders. The company is powered by its proprietary AI-integrated ultra-high-throughput phenotypic drug discovery platform technologies that have enabled the identification of novel small molecules that induce E3 ligase mediated selective degradation of target proteins. From molecular glues to direct degraders, Plexium is advancing a pipeline of novel monovalent targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases.
For more information, visit https://plexium.com/ and engage with us on LinkedIn.
Plexium Investor and
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
